vimarsana.com
  1. Home
  2. Live Updates
  3. Samsung Bioepi Byooviz - Breaking News

Latest Breaking News On - Samsung bioepi byooviz - Page 1 : vimarsana.com

BioBlast w/e 08 Dec 23

The FDA approved Vertex/CRISPR Therapeutics’ Casgevy® and Bluebird Bio’s Lyfgenia®, the first cell-based gene therapies to treat sickle cell disease…

United statesUnited kingdomBio lyfgeniaAstrazeneca merck lynparzaSamsung bioepi byoovizGenentech lucentisGenentech avastinPolpharma biologicsRoche susvimoBristol myers squibbMerck lynparzaSandoz bio thera avziviHealth canadaEuropean medicines agencyNational institute for healthFirst cell based gene therapies casgevy

Doctors largely comfortable with biosimilar drugs, but question economics: report

BioPharma

Amgen amjevitaAbbvie humiraSamsung bioepi byoovizCardinal health

Coherus wins FDA approval for second Lucentis biosimilar, its third drug

BioPharma

United statesRoche genentechCoherus biosciencesSamsung bioepi byoovizDrug administrationDive brief

Ophthalmologists Welcome Genentech s Vabysmo, Though Overthrowing Regeneron s Eylea Will Be No Small Feat, Spherix Reports

/PRNewswire/ Spherix Global Insights, an independent market intelligence firm, recently collected feedback from 103 US ophthalmologists on the neovascular.

Chrystal fergusonSamsung bioepisSamsung bioepi byoovizGenentech vabysmoRegeneron eyleaOur servicesSpherix global insightsRealtime dynamixLaunch dynamixSpecial topixOphthalmology biosimilars todayTime dynamixBiosimilars todayGlobal insightsOphthalmology insights

Ophthalmologists Welcome Genentech s Vabysmo, Though Overthrowing Regeneron s Eylea Will Be No Small Feat, Spherix Reports

/PRNewswire/ Spherix Global Insights, an independent market intelligence firm, recently collected feedback from 103 US ophthalmologists on the neovascular.

Chrystal fergusonSamsung bioepisSamsung bioepi byoovizGenentech vabysmoRegeneron eyleaOur servicesSpherix global insightsRealtime dynamixLaunch dynamixSpecial topixOphthalmology biosimilars todayTime dynamixBiosimilars todayGlobal insightsOphthalmology insights

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.